LEXINGTON, Mass.--(BUSINESS WIRE)-- AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that Brian J.G. Pereira, MD, President and CEO, will provide an update on the Company and the commercial launch of Feraheme® (ferumoxytol) Injection for intravenous (IV) use, at the 29th Annual J.P. Morgan Healthcare Conference on January 10, 2011 at 2:30 p.m. Pacific time.
A live audio webcast of the company’s presentation and the following breakout session along with the accompanying slide presentation will be accessible through the Investors section of the Company’s website at www.amagpharma.com. Following the conference, the webcast will be archived on the AMAG Pharmaceuticals, Inc. website until February 10, 2011.
About AMAG Pharmaceuticals, Inc.
AMAG Pharmaceuticals, Inc. is a biopharmaceutical company that utilizes its proprietary technology for the development and commercialization of a therapeutic iron compound to treat iron deficiency anemia. AMAG manufactures and sells Feraheme® (ferumoxytol) Injection for intravenous (IV) use. For additional company or product information, please visit www.amagpharma.com or http://feraheme.com/.
CONTACT:
AMAG Pharmaceuticals, Inc.
Carol Miceli, 617-498-3361
KEYWORDS: United States North America Massachusetts
INDUSTRY KEYWORDS: Health Biotechnology Pharmaceutical Other Health
MEDIA: